14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.25 $5.48 Wednesday, 1st May 2024 QURE stock ended at $4.57. This is 3.63% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 6.31% from a day low at $4.36 to a day high of $4.64.
90 days $4.25 $6.85
52 weeks $4.25 $22.48

Historical uniQure N.V. prices

Date Open High Low Close Volume
Aug 24, 2021 $28.75 $28.75 $27.30 $28.15 320 242
Aug 23, 2021 $26.68 $28.34 $26.52 $28.04 669 034
Aug 20, 2021 $26.65 $27.43 $26.46 $26.80 724 957
Aug 19, 2021 $27.34 $27.78 $26.42 $26.49 376 784
Aug 18, 2021 $28.79 $28.91 $27.52 $27.68 319 962
Aug 17, 2021 $28.42 $29.03 $28.08 $29.02 275 026
Aug 16, 2021 $28.84 $29.15 $28.25 $28.55 261 767
Aug 13, 2021 $29.39 $29.62 $29.01 $29.16 163 868
Aug 12, 2021 $29.96 $29.97 $29.11 $29.30 220 352
Aug 11, 2021 $29.78 $30.02 $29.26 $29.73 241 246
Aug 10, 2021 $29.63 $29.97 $29.05 $29.62 398 134
Aug 09, 2021 $30.68 $30.84 $29.51 $29.61 251 220
Aug 06, 2021 $30.99 $30.99 $30.04 $30.52 321 432
Aug 05, 2021 $30.05 $31.16 $29.67 $31.11 491 008
Aug 04, 2021 $29.17 $29.81 $29.17 $29.42 191 796
Aug 03, 2021 $28.24 $29.36 $28.24 $29.36 193 366
Aug 02, 2021 $29.40 $29.83 $28.79 $28.95 301 447
Jul 30, 2021 $28.11 $30.06 $28.11 $29.01 540 244
Jul 29, 2021 $30.00 $30.24 $28.84 $29.16 413 459
Jul 28, 2021 $28.30 $29.94 $28.27 $29.74 476 455
Jul 27, 2021 $27.30 $29.06 $27.17 $28.23 710 142
Jul 26, 2021 $26.52 $27.89 $26.06 $27.01 651 081
Jul 23, 2021 $26.53 $26.53 $25.80 $26.01 319 186
Jul 22, 2021 $27.21 $27.36 $26.05 $26.49 182 820
Jul 21, 2021 $26.55 $27.34 $26.18 $27.12 194 657
Click to get the best stock tips daily for free!

About uniQure N.V.

uniQure N.V. uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phas... QURE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT